“If LDL-C lowering was the first revolution in preventive cardiology, the incorporation of ApoB and Lp(a) marks the beginning of the second, one rooted in particle biology, genetic risk, and refined precision prevention.”
Wiggins et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: